Your Insurance Dropped GLP-1 Coverage. Here's What to Do Next.

In 2026, Blue Cross Blue Shield of Massachusetts announced it would stop covering GLP-1 medications for obesity, citing the impact on insurance premiums. Their suggestion to affected patients: buy the drugs directly from manufacturers at self-pay prices.

They're not alone. Across the country, insurers are implementing stricter prior authorization requirements, raising BMI thresholds for coverage, limiting treatment duration, or dropping coverage entirely. If this is happening to you, you have options. Here they are, in order of priority.

Step 1: Understand Why Coverage Was Denied

Not all denials are the same. Get the specific reason in writing from your insurer. The most common scenarios:

• "Not medically necessary" — The insurer doesn't consider your situation severe enough. This is the most appealable denial.
• "Not a covered benefit" — The plan categorically excludes weight loss medications. This is harder to appeal but not impossible.
• "Prior authorization required" — Your doctor didn't complete the required paperwork. This is a process issue, not a true denial.
• "Step therapy required" — You need to try a cheaper medication first (like Contrave or phentermine) before the insurer will cover a GLP-1.

Step 2: Appeal (If Applicable)

If the denial is based on medical necessity or prior authorization, you have the right to appeal. Success rates on GLP-1 appeals are higher than many patients realize, particularly if you can demonstrate:

• Documented BMI history showing obesity is a chronic condition
• Failed attempts at lifestyle modification (diet, exercise programs)
• Comorbid conditions that would improve with weight loss (diabetes, hypertension, sleep apnea)
• Your physician's clinical justification for GLP-1 specifically

Your doctor's office may have staff experienced with prior authorization appeals. Ask them to handle it — they do this regularly.

Step 3: Check Manufacturer Programs

Both major GLP-1 manufacturers offer patient assistance:

• Novo Nordisk — Wegovy self-pay pricing at approximately $349/month through their direct program. Savings cards may be available for commercially insured patients.
• Eli Lilly — Zepbound pricing programs, LillyDirect platform for direct-to-patient access, and the upcoming Foundayo oral at competitive pricing.

Step 4: Consider Telehealth Providers

If insurance isn't an option and manufacturer self-pay pricing is too high, telehealth providers offering compounded GLP-1 medications may provide the most accessible path. Prices typically range from $99–$399/month depending on the provider and medication.

Step 5: Explore Medicare (If Eligible)

If you're a Medicare beneficiary, the landscape is about to change dramatically. The Medicare GLP-1 Bridge program launches July 1, 2026, offering covered GLP-1 medications at $50/month. This applies to brand-name Wegovy, Zepbound, and Foundayo — not compounded medications.

Step 6: Consider the Diabetes Pathway

If you have type 2 diabetes, GLP-1 medications like Ozempic and Mounjaro are FDA-approved for diabetes management — and insurance coverage for diabetes medications is generally much broader than for weight loss. Your doctor may be able to prescribe a GLP-1 for your diabetes that also produces weight loss as a secondary benefit.

This isn't "gaming the system" — if you have both obesity and diabetes, treating both conditions simultaneously is sound medical practice.

What Not to Do

• Don't buy from unverified online sources. The FDA has identified counterfeit GLP-1 products being sold online. Only use licensed pharmacies and verified telehealth platforms.
• Don't stop medication abruptly without talking to your provider. If cost is forcing a change, discuss tapering strategies or switching to a more affordable option.
• Don't assume you're out of options. The GLP-1 market is the most competitive it's ever been, with prices dropping and new products launching regularly. An option that didn't exist three months ago might be available now.